Core Viewpoint - The company, Entropy Technology, received a warning letter from the Guangdong Securities Regulatory Commission regarding violations in revenue recognition, bad debt provision, R&D expense accounting, inventory impairment provision, and related party transaction disclosures [1] Group 1 - The company has been identified for non-compliance in several financial reporting areas [1] - The company and responsible parties are required to rectify the issues and submit a written report [1]

证券代码：301330 证券简称：熵基科技 公告编号：2026-002 熵基科技股份有限公司 关于收到广东证监局警示函的公告 （四）存货跌价准备计提不准确。经查，熵基科技子公司 ZKTECO USA LLC 实 际 销 售 费 用 率 为 57% ， 但 在 存 货 跌 价 测 试 中 参 考 另 一 子 公 司 ZK TECHNOLOGY LLC 15%的销售费用率，缺乏合理依据，高估可变现净值，导致 熵基科技 2024 年存货跌价准备计提不准确，上述情形不符合《企业会计准则第 1 号——存货》第十六条的规定，违反了《上市公司信息披露管理办法》第三条 第一款的规定。 （五）关联交易披露不准确。ZKTECO SOLUTIONS INC.为熵基科技关联方、 联营企业。公司《2024 年年度报告》"十四、关联方及关联交易"部分披露， 2024 年与 ZKTECO SOLUTIONS INC.关联交易金额为 1134.43 万元。经查，熵 基科技 2024 年对 ZKTECO SOLUTIONS INC.实际销售金额为 1890.72 万元，与 公司披露的关联交易金额不一致，上述情形违反了《上市公司信息披露管理办法 ...

Core Viewpoint - The company, Entropy Technology (301330.SZ), plans to launch a prototype for its brain-computer interface business by March 2026, with no sales revenue generated from brain-computer products to date [1]. Group 1 - The brain-computer interface business is expected to release a prototype in March 2026 [1]. - Currently, the brain-computer products have not generated any sales revenue [1]. - The company has advised investors to be aware of investment risks associated with this business [1].

瑞银证券有限责任公司 关于熵基科技股份有限公司 2025 年定期现场检查报告 | 保荐机构名称：瑞银证券有限责任公司 被保荐公司简称：熵基科技（301330） | | | --- | --- | | 保荐代表人姓名：宫乾 联系电话：010 – 58328888 | | | 保荐代表人姓名：蔡志伟 联系电话：010 – 58328888 | | | 现场检查人员姓名：宫乾、蔡志伟、孟洁 | | | 年 月 年 月 日 现场检查对应期间：2024 12 1 日-2025 11 30 | | | 现场检查时间：2025 年 月 日 12 23 | | | 一、现场检查事项 现场检查意见 | | | （一）公司治理 是 否 | 不适用 | | 现场检查手段：对上市公司高级管理人员及有关人员进行访谈、现场查看公司主要管理场所、 | | | 查阅公司股东会、董事会材料、公司章程等制度等 | | | 1.公司章程和公司治理制度是否完备、合规 √ | | | 2.公司章程和股东会、董事会规则是否得到有效执行 √ | | | 3.股东会、董事会会议记录是否完整，时间、地点、出席人 √ | | | 员及会议内容等要件是否齐备，会 ...

瑞银证券有限责任公司 关于熵基科技股份有限公司 2025年持续督导培训情况报告 根据《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》要求， 瑞银证券有限责任公司（以下简称"瑞银证券"）作为熵基科技股份有限公司（以 下简称"熵基科技"或"公司"）首次公开发行股票并在创业板上市的持续督导机构， 于 2025 年 12 月 23 日对熵基科技董事、高级管理人员及实际控制人和其他相关 人员进行了培训。 一、培训的基本情况 实施本次培训前，瑞银证券编制了培训材料，并提前要求熵基科技参与培训 的相关人员了解培训相关内容。 二、培训的主要内容 培训主要内容为上市公司治理结构，上市公司独立性，上市公司董事、高级 管理人员股份变动管理及避免内幕交易、募集资金管理和使用相关内容。 三、培训结论 通过本次培训，有助于加强熵基科技董事、高级管理人员等对上市公司规范 运作相关监管法规的熟悉和深入理解，本次培训达到预期效果。 （以下无正文） （此页无正文，为《瑞银证券有限责任公司关于熵基科技股份有限公司 2025 年 持续督导培训情况报告》之签章页） 保荐代表人签名： 本次培训的地点为熵基科技股份有限公司，培训人员为宫乾， ...

| 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603516 享中科技 | | 1.85 Z | 9.40% | -1.15 Z | -5.83% | -7033.69万 | -3.58% | | 301589 诺瓦星云 | | 8118.50万 | 12.54% | 1274.26万 | 1.97% | -9392.76万 | -14.51% | | 301330 熵基科技 | | 7138.80万 | 4.64% | 264.87万 | 0.17% | -7403.67万 | -4.82% | | 002970 锐明技术 | | 5987.25万 | 7.03% | -3473.04万 | -4.08% | -2514.22万 | -2.95% | | 300302 同有科技 | | 5886.93万 | 6.53% | 2715.20万 | 3.01% | -8602.13万 | -9.55% | | 3005 ...

Group 1 - The brain-computer interface sector in the A-share market experienced a significant decline, with multiple companies reporting substantial drops in their stock prices [1] - Major companies such as Mailland, Chengyitong, and Aipeng Medical saw declines exceeding 10%, while others like Leidi Ke and Weisi Medical dropped over 8% [1][2] - Several brain-computer interface concept stocks issued announcements indicating a cooling off, with companies like Aerospace Changfeng stating they have not actually engaged in related business activities [1] Group 2 - Mailland's stock fell by 11.09%, with a total market value of 54.43 billion [2] - Chengyitong's stock decreased by 10.91%, with a market capitalization of 6.731 billion [2] - Aipeng Medical's stock dropped by 10.39%, with a market value of 4.514 billion [2]

Core Viewpoint - The A-share market has seen a significant pullback in several brain-computer interface (BCI) concept stocks, with notable declines among various companies [1] Group 1: Stock Performance - Companies such as 麦澜德 (Mikland) and 熵基科技 (Entropy Technology) experienced declines exceeding 10% [1] - 诚益通 (Chengyi Tong) and 雷迪克 (Redik) fell over 7% [1] - 博拓生物 (Botuo Bio) and 爱朋医疗 (Aipeng Medical) dropped more than 6% [1] - 可孚医疗 (Kefu Medical) and 翔宇医疗 (Xiangyu Medical) decreased over 5% [1] - 狄耐克 (Dinaike) and 伟思医疗 (Weisi Medical) saw declines greater than 4% [1] Group 2: Company Announcements - Multiple BCI concept stocks issued announcements indicating a cooling off in the market [1] - 航天长峰 (Aerospace Changfeng) stated that the company has not actually engaged in BCI-related business [1] - 伟思医疗 (Weisi Medical) mentioned that new products in the BCI field are still in the early stages of market cultivation [1]

Group 1 - The A-share market has seen a significant pullback in brain-computer interface (BCI) concept stocks, with notable declines in companies such as Mailland and Entropy Technology, which fell over 10% [1] - Several BCI concept stocks have issued announcements indicating a cooling off, with Aerospace Changfeng stating that it has not actually engaged in BCI-related business [1] - Weisi Medical mentioned that its new products in the BCI field are still in the early stages of market cultivation [1] Group 2 - Specific stock performance includes Mailland down 10.68% with a market cap of 5.468 billion, Entropy Technology down 10.13% with a market cap of 10.1 billion, and Chengyi Tong down 7.55% with a market cap of 6.985 billion [2] - Other notable declines include Leedick down 7.14%, Botao Biological down 6.37%, and Aipeng Medical down 6.38% [2] - The overall trend shows that many BCI-related stocks are experiencing a downturn, with declines ranging from 4.33% to 10.68% across various companies [2]

Core Viewpoint - The brain-computer interface (BCI) concept continues to gain traction, with multiple listed companies responding positively to the trend, leading to significant stock price increases in the sector [1]. Company Responses - On January 6, several companies, including Weisi Medical, Sanbo Brain Science, Aipeng Medical, and others, saw their stocks hit the daily limit, with many achieving consecutive gains [3]. - Weisi Medical reported a 20.01% increase in stock price, indicating a strong market response to its developments in the neuro-rehabilitation field, expanding from single-device solutions to comprehensive "diagnosis-treatment-rehabilitation" offerings [4][5]. - Sanbo Brain Science highlighted the promising applications of BCI technology in clinical diagnosis and neuro-rehabilitation, also achieving a 20.01% stock price increase [7]. - Xiangyu Medical announced the establishment of a BCI laboratory and aims to develop a product system covering four major categories, also achieving a two-day stock increase [8]. - Aipeng Medical's stock rose by 20%, emphasizing the role of BCI as a bridge between the brain and external devices [9][10]. - Entropy Technology and Meihua Medical also reported significant stock increases, with the former focusing on BCI and vehicle-road collaboration technologies [11][12]. Industry Developments - Companies are actively engaging in the BCI sector, with Xiangyu Medical entering over 500 medical institutions and aiming for over a thousand top-tier hospitals nationwide, indicating a robust commercialization strategy [15]. - Mcland anticipates obtaining its first BCI medical device registration certificate by Q1 2026, which could accelerate the application of BCI technology in existing product lines [15]. - Chengdu Huayi and Yingjixin are focusing on the foundational hardware for BCI, with Chengdu Huayi developing high-precision ADCs and low-power FPGAs for signal processing [15][16]. - The integration of BCI with embodied intelligence is gaining attention, with companies exploring applications in smart healthcare and rehabilitation [17]. - Blue Si Technology announced its strategic investment in Qiang Brain Technology, which recently secured approximately 2 billion yuan in funding, marking it as the second-largest financing in the BCI field after Neuralink [18]. Market Outlook - The global BCI market is projected to reach approximately $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034, driven by technological advancements and increased capital investment [20]. - The transition of BCI from clinical validation to commercial scalability is expected to unlock significant market opportunities in healthcare and consumer sectors [20].